Volume 22, Issue 2 (Iranian South Medical Journal 2019)
Iran South Med J 2019, 22(2): 106-118 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Afarid M, Heidari M, Assadi M. Serum Levels of Interferon-Gamma in Patients with Diabetic Retinopathy. Iran South Med J 2019; 22 (2) :106-118
URL: http://ismj.bpums.ac.ir/article-1-1070-en.html
URL: http://ismj.bpums.ac.ir/article-1-1070-en.html
1- Department of ophthalmology , Poostchi Ophthalmology Resarch Center, Shiraz Medical school, Shiraz university of medical Sciences, Shiraz, Iran
2- The Persian Gulf Nuclear Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran , msassadi16@yahoo.com
2- The Persian Gulf Nuclear Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran , msassadi16@yahoo.com
Abstract: (3445 Views)
Background: In recent years, numerous studies have addressed the role of other factors, especially the immune system, on developing diabetic retinopathy. Given the role of interferons in regulating immune system activities, the present study was conducted to investigate serum levels of interferon-gamma in patients with diabetic retinopathy.
Materials and Methods: The present research was conducted on 42 patients with type 2 diabetes and diabetic retinopathy in the case group and 41 patients with only type 2 diabetes in the control group. The two groups were matched in terms of age and gender. In the previous three months, the participants had not developed severe bacterial, viral or parasitic infections, not undergone ocular and non-ocular surgeries and not taken immunosuppressants. After measuring the patients’ systolic and diastolic blood pressures, their urine and blood samples were collected for the laboratory analysis of CBC, LDL, HDL, TG, total cholesterol, proteinuria, FBS, HbA1c, ESR, CRP, BUN, Creatinine and interferon gamma. The data collected were statistically analyzed in SPSS-18.
Results: Out of 83 patients aged 41-78 years with type 2 diabetes, 42 patients were assigned to the case group and 41 to the control group. The mean of age of the case group was 59.69±6.866 years and that of the controls 58.71±7.410. Based on statistical methods, the two groups were matched in terms of age and gender. Although serum levels of interferon gamma were higher in the case group compared to in the controls, the difference was statistically insignificant (P>0.05). No significant differences were also observed between the two groups in terms of WBC, LDL, total cholesterol, FBS, CRP, Creatinine, HDL and diastolic blood pressure (P>0.05). According to the logistic regression model, the risk of developing retinopathy was approximately 8 times higher in the insulin users compared to in those using oral medicines.
Conclusion: The statistical analysis and regression model did not suggest significant relationships between serum levels of interferon gamma and diabetic retinopathy. The two groups were significantly different in terms of insulin consumption. Further studies are recommended to be conducted to find the role of immunological factors in developing diabetic retinopathy.
Materials and Methods: The present research was conducted on 42 patients with type 2 diabetes and diabetic retinopathy in the case group and 41 patients with only type 2 diabetes in the control group. The two groups were matched in terms of age and gender. In the previous three months, the participants had not developed severe bacterial, viral or parasitic infections, not undergone ocular and non-ocular surgeries and not taken immunosuppressants. After measuring the patients’ systolic and diastolic blood pressures, their urine and blood samples were collected for the laboratory analysis of CBC, LDL, HDL, TG, total cholesterol, proteinuria, FBS, HbA1c, ESR, CRP, BUN, Creatinine and interferon gamma. The data collected were statistically analyzed in SPSS-18.
Results: Out of 83 patients aged 41-78 years with type 2 diabetes, 42 patients were assigned to the case group and 41 to the control group. The mean of age of the case group was 59.69±6.866 years and that of the controls 58.71±7.410. Based on statistical methods, the two groups were matched in terms of age and gender. Although serum levels of interferon gamma were higher in the case group compared to in the controls, the difference was statistically insignificant (P>0.05). No significant differences were also observed between the two groups in terms of WBC, LDL, total cholesterol, FBS, CRP, Creatinine, HDL and diastolic blood pressure (P>0.05). According to the logistic regression model, the risk of developing retinopathy was approximately 8 times higher in the insulin users compared to in those using oral medicines.
Conclusion: The statistical analysis and regression model did not suggest significant relationships between serum levels of interferon gamma and diabetic retinopathy. The two groups were significantly different in terms of insulin consumption. Further studies are recommended to be conducted to find the role of immunological factors in developing diabetic retinopathy.
Type of Study: Original |
Subject:
Ophthalmology
Received: 2018/03/4 | Accepted: 2019/02/18 | Published: 2019/05/18
Received: 2018/03/4 | Accepted: 2019/02/18 | Published: 2019/05/18
References
1. Eliashiv A, Olumide F, Norton L, et al. Depression of Cell-mediated Immunity in Diabetes. Arch Surg 1978; 113(10): 1180-3. [DOI:10.1001/archsurg.1978.01370220066011]
2. Zarghami N, Bahari Vand N, Mahdavi Fard A, et al. Relationship Between the Level of Vascular Endothelial Growth Factor VEGF (VEGF) and Serum VEGF Levels, Diabetes Control and Microalbuminuria in Diabetic Proliferative Retinopathy. Iran J Diabetes Metab 2008; 8(1): 45-54. (Persian)
3. Maheshwari RK, Srikantan V, Bhartiya D, et al. Differential Effects of Interferon Gamma and Alpha on in Vitro Model of Angiogenesis. J Cell Physiol 1991; 146(1): 164-9. [DOI:10.1002/jcp.1041460121]
4. Ray D, Mishra M, Ralph S, et al. Association of the VEGF Gene with Proliferative Diabetic Retinopathy But Not Proteinuria in Diabetes. Diabetes 2004; 53(3): 861-4. [DOI:10.2337/diabetes.53.3.861]
5. Adamis AP, Miller JW, Bernal MT, et al. Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes with Proliferative Diabetic Retinopathy. Am J Ophthalmol 1994; 118(4): 445-50. [DOI:10.1016/S0002-9394(14)75794-0]
6. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, et al. IFN-gamma Gene Expression in Pancreatic Islet-Infiltrating Mononuclear Cells Correlates with Autoimmune Diabetes in Nonobese Diabetic Mice. J Immunol 1995; 154(9): 4874-82.
7. von Herrath MG, Oldstone MB. Interferon-γ is Essential for Destruction of β Cells and Development of Insulin-dependent Diabetes Mellitus. J Exp Med 1997; 185(3): 531-9. [DOI:10.1084/jem.185.3.531]
8. Jakelić J, Kokić S, Hozo I, et al. Nonspecific Immunity in Diabetes: Hyperglycemia Decreases Phagocytic Activity of Leukocytes in Diabetic Patients. Medicinski Arhiv 1995; 49(1-2): 9-12.
9. Geerlings SE, Hoepelman AI. Immune Dysfunction in Patients with Diabetes Mellitus (DM). FEMS Immunol Med Microbiol 1999; 26(3-4): 259-65 [DOI:10.1111/j.1574-695X.1999.tb01397.x]
10. Sobel DO, Newsome J. Gamma Interferon Prevents Diabetes in the BB Rat. Clin Diagn Lab Immunol 1997; 4(6): 764-8.
11. Belperio JA, Keane MP, Arenberg DA, et al. CXC Chemokines in Angiogenesis. J Leukoc Biol 2000; 68(1): 1-8.
12. Âfkhami Ardakani M, Modaresi M, Âmirchaghmaghi E. Prevalence of Microalbuminuria in Type 2 Diabetic Patients Reffered to Yazd Diabetes Research Centre. J Mazandaran Univ Med Sci 2004; 14 (43): 49-56.
13. Rasoulinejad SA, Hajian-Tilaki K, Mehdipour E. Associated Factors of Diabetic Retinopathy in Patients that Referred to Teaching Hospitals in Babol. Caspian J Intern Med 2015; 6(4): 224-8.
14. Meleth AD, Agrón E, Chan CC, et al. Serum Inflammatory Markers in Diabetic Retinopathy. Invest Ophthalmol Vis Sci 2005; 46(11): 4295-301. [DOI:10.1167/iovs.04-1057]
15. Safaei H, Amini M, Behroz J, et al. Retinopathy in Newly Diagnosed Typ 2 Diabetec Patients in Isfahan, Prevalence and Risk Factors. Iran J diabetes Metab 2006; 5(3): 236-43.
16. Mohan VA, Nithyanandam S, Idiculla J. Microalbuminuria and Low Hemoglobin as Risk Factors for the Occurrence and Increasing Severity of Diabetic Retinopathy. Indian J Ophthalmol 2011; 59(3): 207-10. [DOI:10.4103/0301-4738.81029]
17. Jew OM, Peyman M, Chen TC, et al. Risk Factors for Clinically Significant Macular Edema in a Multi-ethnics Population with Type 2 Diabetes. Int J Ophthalmol 2012; 5(4): 499-504.
18. Muni RH, Kohly RP, Lee EQ, et al. Prospective Study of Inflammatory Biomarkers and Risk of Diabetic Retinopathy in the Diabetes Control and Complications Trial. JAMA Ophthalmol 2013; 131(4): 514-21. [DOI:10.1001/jamaophthalmol.2013.2299]
19. Omidi M, Nakhjavani M, Dodgar F, et al. Serum Levels of TNF-α and CRP in Type 2 Diabetic Patients with Diabetic Retinopathy and Comparison with Control Group. Iran J Diabetes Metab 2010; 10(1): 76-83. (Persian)
20. Magri C.J, Calleja. N , Buhagiar. G , et al. Factors associated with diabetic nephropathy in subjects with proliferative retinopathy, International Urology and Nephrology, 2012(4): 197-206. [DOI:10.1007/s11255-011-9958-1]
21. Hernández-Da Mota SE, Soto-Bahena JJ, Viveros-Sandoval ME, et al. Pro-inflammatory serum cytokines in diabetic retinopathy,Cirugía y Cirujanos 2015(83)(2):100-6. [DOI:10.1016/j.circen.2014.09.002]
22. Zaidi A, Waheed P, Rashid A. The relation of C-reactive protein, erythrocyte sedimentation rate and body mass index with diabetic retinopathy in patient enrolled from tertiary care hospital. Pak Armed Forces Med J 2017; 67(6): 926-9.
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
